Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$9.39 USD
+0.88 (10.34%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $9.40 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
Scholar Rock Holding Corporation [SRRK]
Reports for Purchase
Showing records 1 - 20 ( 136 total )
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
TOPAZ 48-Month Data Continues to Shine as Phase 3 SAPPHIRE Study Expected in 4Q24: Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Preclinical Data During ADA?24 Leave Us Hungry (and Fit) for SRK-439?s Potential
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Mighty Mouse: Have Your Shake and Eat It Too
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
DRAGON?s (SRK-181+ Pembro) ASCO Update Makes a Case for ccRCC
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Friendly Reminder: It''s Still the Year of the DRAGON
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
The Future of Obesity Therapeutics-Takeaways from European Obesity Conference in Venice
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Muscle Matters While Fat Shatters, and Other Highlights from SRRK?s Investor Day
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab Progress Across SMA and Obesity Remains Strong
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab?s SAPPHIRE Data in SMA (4Q24) Remains Key Focus, With Obesity Start in mid-2024; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A